Chemotherapy protocol: All pts had premedication with B12 injection, oral folic acid and dexamethasone. Pemetrexed 500mg/m2 and Carboplatin dose AUC 5 (Calvert’s formula) intravenous infusions, every 3 weeks. All pts had clinic review and blood tests prior to each cycle. The following data was...
Protocol H3E-MC-JMHO A Randomized Phase 3 Trial of ALIMTA® (Pemetrexed) and Carboplatin versus Etoposide and Carboplatin in Extensive-Stage Small Cell L... FV Fossella 被引量: 0发表: 2015年 Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. Mammalian cells contain two...
The objective of this study was to evaluate the efficacy and safety of pemetrexed plus cisplatin/carboplatin in locally advanced or metastatic non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy. Methods Fifty-three locally advanced or metastatic non-small cel...
Eligible patients were randomized 1:1 to 4 to 6 cycles of camrelizumab plus carboplatin and pemetrexed or chemotherapy alone every 3 weeks, followed by maintenance camrelizumab plus pemetrexed or pemetrexed only (n = 205 and 207, respectively). Total camrelizumab exposure was up to 2 yea...
The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM). Methods: Eligible ...
absolute neutrophil count (ANC) is 1500 cells/mm³ or higher, and platelet count is 100,000 cells/mm³ or higher. Upon recovery, modify the dosage of ALIMTA in the next cycle as specified in Table 1. For dosing modifications for cisplatin, carboplatin, or pembrolizumab, refer to their ...
A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung ... Y Kogure,H Hashimoto,M Oki - 《Clinical Lung Cancer》 被引量: 0发表: 2021年 KEYNOTE-062: Phase 3 study of pembrolizumab alone or in...
Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD (2009b) Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer. J Clin Oncol 27: 3284–3289. Artic...
1 death). The one treatment-related death occurred from sepsis associated with nonimmune-related renal and respiratory failure. Eighteen patients with stable disease or partial response proceeded tosurgical resection; 17 received a P/D and 1 EPP. One patient did not receive protocol-specified surger...
The primary endpoint of this trial was the 3-year survival rate.& para;& para;Results: Forty-six patients began protocol treatment, and 40 completed 4 courses of pemetrexed/carboplatin. Surgical resection was performed in 27 patients (59%); all had pathologic partial responses. The estimated 3...